title: CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy.
abstract: Ca2+/calmodulin-dependent protein kinase (CaMK) is an important downstream target of Ca2+ in the hypertrophic signaling pathways. We previously showed that the activation of apoptosis signal-regulating kinase 1 (ASK1) or NF-kappaB is sufficient for cardiomyocyte hypertrophy. Infection of isolated neonatal cardiomyocytes with an adenoviral vector expressing CaMKIIdelta3 (AdCaMKIIdelta3) induced the activation of ASK1, while KN93, an inhibitor of CaMKII, inhibited phenylephrine-induced ASK1 activation. Overexpression of CaMKIIdelta3 induced characteristic features of in vitro cardiomyocyte hypertrophy. Infection of cardiomyocytes with an adenoviral vector expressing a dominant negative mutant of ASK1 (AdASK(KM)) inhibited the CaMKIIdelta3-induced hypertrophic responses. Overexpression of CaMKIIdelta3 increased the kappaB-dependent promoter/luciferase activity and induced IkappaBalpha degradation. Coinfection with AdCaMKIIdelta3 and AdASK(KM), and pre-incubation with KN93 attenuated CaMKIIdelta3- and phenylephrine-induced NF-kappaB activation, respectively. Expression of a degradation resistant mutant of IkappaBalpha inhibited CaMKIIdelta3-induced hypertrophic responses. These results indicate that CaMKIIdelta3 induces cardiomyocyte hypertrophy mediated through ASK1-NF-kappaB signal transduction pathway.
authors.affiliation: Department of Internal Medicine and Therapeutics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kashiwase
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hirotani
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: Shungo
authors.initials: S
authors.lastname: Hikoso
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Takeda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Watanabe
authors.forename: Masayuki
authors.initials: M
authors.lastname: Taniike
authors.forename: Atsuko
authors.initials: A
authors.lastname: Nakai
authors.forename: Ikuko
authors.initials: I
authors.lastname: Tsujimoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Matsumura
authors.forename: Hikaru
authors.initials: H
authors.lastname: Ueno
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nishida
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Hori
authors.forename: Kinya
authors.initials: K
authors.lastname: Otsu
mesh_terms: D000818:Animals; D002118:Calcium / Q000494:pharmacology; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000235:genetics / Q000378:metabolism*; D006332:Cardiomegaly / Q000378:metabolism* / Q000473:pathology; D002478:Cells, Cultured; D004789:Enzyme Activation / Q000187:drug effects; D005786:Gene Expression Regulation; D006861:Hydrogen Peroxide / Q000494:pharmacology; D048848:MAP Kinase Kinase Kinase 5 / Q000235:genetics / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000378:metabolism* / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction
chemical_list: D016328:NF-kappa B; D006861:Hydrogen Peroxide; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D048848:MAP Kinase Kinase Kinase 5; D002118:Calcium